AI Article Synopsis
- The study measured inflammatory markers and neopterin levels in women with and without PCOS, comparing obese and non-obese groups along with BMI-matched controls.
- Results showed higher neutrophil-to-lymphocyte (N/L) ratios and lower vitamin B12 levels in PCOS patients, while CRP levels were higher in obese PCOS patients compared to obese controls.
- The findings suggest that inflammatory activity associated with PCOS may raise atherosclerosis risks, indicating that this inflammation is linked more to PCOS itself rather than obesity, though more research is needed.
Article Abstract
Background: We aimed to measure the levels of inflammatory markers and neopterin in obese and non-obese patients with PCOS by using 2 separate control groups with matching body mass index (BMI).
Material And Methods: A total of 60 women of reproductive age with (n=30) and without (n=30) PCOS were included in this study. Based on their BMI, patients with PCOS were divided into 2 groups as obese (n=15) and non-obese (n=15) PCOS groups. In addition, 2 BMI-matched control groups were formed. Neopterin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (N/L ratio), and vitamin B12 were assessed by complete blood count.
Results: No significant difference was found between patients with PCOS and control subjects in neopterin, IL-6, TNF-α, and CRP levels. However, N/L ratio levels were significantly higher (p 0.045) and vitamin B12 levels were significantly lower (p 0.033) in patients with PCOS compared to control subjects. No statistically significant difference was found between obese and non-obese patients with PCOS and control subjects in neopterin, IL-6, TNF-α, and N/L ratio levels. However, CRP levels were significantly higher in obese patients with PCOS compared to obese control subjects (p 0.007).
Conclusions: It can be concluded that inflammatory activity is increased in patients with PCOS, can lead to an increased risk for atherosclerosis, and this increase is not caused by obesity but rather by the polycystic ovary syndrome itself. However, studies with larger sample sizes are needed in this area.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548699 | PMC |
| http://dx.doi.org/10.12659/MSM.894368 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oviduct Glycoprotein 1 (OVGP1) Diagnoses Polycystic Ovary Syndrome (PCOS) Based on Machine Learning Algorithms.
ACS Omega
December 2024
Department of Clinical Laboratory Medicine, Xijing Hospital, Fourth Military Medical University (Air Force Military Medical University), Xi'an 710032, China.
: To investigate the diagnostic value of oviduct glycoprotein 1 (OVGP1) levels for polycystic ovary syndrome (PCOS). : Serum OVGP1 concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Associations between OVGP1 and endocrine parameters were evaluated by Spearman's correlation analysis.
View Article and Find Full Text PDFMicroRNAs as Biomarkers for Metabolic Disorders in Polycystic Ovary Syndrome (PCOS): A Review.
Med Sci Monit
December 2024
Independent Laboratory of Minimally Invasive Gynecology and Gynecological Endocrinology, Medical University of Lublin, Lublin, Poland.
Polycystic ovary syndrome (PCOS) is associated with several mild metabolic disorders, including insulin resistance (IR), obesity, and dyslipidemia, as well as with some more severe ones, including type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease. Clinically, mild metabolic complications of PCOS such as IR or lipid metabolism disorders are the predictors of these more severe ones. So far, there is no reliable single marker that enables defining metabolic risk in patients with PCOS.
View Article and Find Full Text PDFMediating role of anxiety between body image distress and quality of life among women with polycystic ovary syndrome: a multicentre cross-sectional study.
BMC Womens Health
December 2024
Nursing Department, The Third Xiangya Hospital, Central South University, Changsha, China.
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. Body image distress (BID) refers to psychological distress caused by deviations in the individual's self-aesthetic ability. The objectives of this study are to investigate the prevalence of psychological distress; and to assess the role of anxiety in the relationship between body image distress and quality of life (QoL) among women with polycystic ovary syndrome using a path analysis approach.
View Article and Find Full Text PDFClinical significance and biological roles of lncRNA CTBP1-AS in polycystic ovary syndrome.
J Ovarian Res
December 2024
Reproductive Medicine Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Polycystic ovary syndrome (PCOS) is among the most prevalent endocrine and metabolic disorders affecting women of reproductive age. Multiple factors, including genetic predisposition, environmental influences, and lifestyle choices, are considered significant contributors to the development of PCOS. A kind of long noncoding RNA-C-Terminal binding protein 1 antisense (lncRNA CTBP1-AS) has been proven to be a new androgen receptor regulator.
View Article and Find Full Text PDFComparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome in women with polycystic ovary syndrome: a systematic review and network meta-analysis.
J Ovarian Res
December 2024
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Purpose: To compare the efficacy and safety of metformin, anti-obesity agents, and inositol with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
Methods: A comprehensive search was conducted in PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov for studies published in English up to October 26, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!